This trial is active, not recruiting.

Condition x-linked severe combined immunodeficiency
Treatment gene transfer
Phase phase 1/phase 2
Sponsor Assistance Publique - Hôpitaux de Paris
Start date December 2010
End date July 2015
Trial size 5 participants
Trial identifier NCT01410019, 2008-002380-14, P071204


X-linked severe combined immunodeficiency (SCID-X1) is an inherited disorder that results in failure of development of the immune system in boys. This trial aims to treat SCID-X1 patients using gene therapy to replace the defective gene.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Gene transfer
gene transfer
Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) GAMMARETROVIRAL vector pSRS11.EFS.IL2RG.pre

Primary Outcomes

Assessment of immunological reconstitution at short term
time frame: month 4

Secondary Outcomes

Molecular characterization of gene transfer
time frame: every 15 days during 3 months, once per month until 6 months, every 3 months until year 1, every year until year 10
Analysis of activated proto-oncogene s expression
time frame: every 4 months during 2 years and every 6 months indefinitely

Eligibility Criteria

Male participants up to 12 months old.

Inclusion criteria : - Boys diagnosed during the first year of life - Diagnosis of classical SCID-X1 based on immunophenotype (absent, or reduced numbers of non-functional T lymphocytes) and confirmed by DNA sequencing - No HLA identical family donor and no HLA identical unrelated donor (10/10 antigens) found in the 6 weeks following the beginning of the search. This period could be shortened if the probability to find a donor is low or if the clinical situation (gravity) required - Presence of a severe infection: pneumonitis and / or chronic diarrhea, or infection with herpes viruses or parainfluenza type 3 or adenovirus, or disseminated BCG infection, or presence of severe diarrhea and a severe compromise of the general state with denutrition - Or failure of a HLA HAPLO-identical bone marrow transplant within 10 years after transplantation - In all cases: - No family background of cancer in childhood. - No cytogenetic abnormalities (medullary karyotype) and no detection of main rearrangements associated with acute leukemia of children - Parental/guardian voluntary consent Exclusion criteria : - Atypical health with autologous T> 500/ml3 - Infection by HIV 1 or 2 - Allogeneic HSC completed (excluding situations of failure) - Existence of an HLA identical family donor or HLA identical unrelated donor - No severe infections in a child with a preserved general state - Family background of cancer in childhood - Detection of cytogenetic abnormality and / or rearrangement associated with acute leukemia of children - No affiliation to a social security scheme (beneficiary or assignee)

Additional Information

Official title Protocol No. 2 of Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1) Using a Self Retroviral Vector - SCID2
Description The objective of this protocol is to reinitiate an ex vivo gene therapy clinical protocol to treat patients with SCID-X1 without HLA identical family donor nor HLA identical unrelated donor (bone marrow and cord blood) available in an adequate time with the clinical conditions of the patient at diagnosis (approximately 6 weeks). This clinical protocol No. 2 of SCID-X1 must be as efficient than the previous one but must involve a risk of insertional mutagenesis significantly reduced as compared to the first protocol. The main purpose of the study is the study of toxicity: tolerance and incidence of serious adverse effects. Secondary goals are the evaluation of immune reconstitution allowing the cure of infections present at the time of gene therapy, assessment of integration sites, and finally the long-term correction of immunosuppression. 1. safety assessment : clinical effects, possible emergence of clonal lymphocyte proliferation, potential activation of proto-oncogene; 2. efficacy assessment of ex vivo transduction of CD34 + hematopoietic stem cells of the patient through the use of retroviral vector pSRS11.EFS.IL2RG.pre; 3. assessment of immune reconstitution : phenotype, number and function of different T, NK and B cells subpopulations; 4. longitudinal evaluation of clinical effects in terms of improvement or complete restoration of immunity; 5. biological efficacy assessment of this new vector SIN, assessment of molecular characteristics of retroviral integration.
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris.